Revelation Biosciences, Inc. (REVBW) stock
REVBWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVB
$0.01+0.00 (0.00%)
Close on Oct 30, 2026Market cap $16.05MP/E –Yield –
Revelation Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Revelation Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$11.27M. For fiscal 2025 it was -$9.07M. The highest annual figure on record is -$7.98M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.07M | – |
| FY2024 | Dec 31, 2024 | -$7.98M | – |
| FY2023 | Dec 31, 2023 | -$8.66M | – |
| FY2022 | Dec 31, 2022 | -$10.86M | – |
| FY2021 | Dec 31, 2021 | -$11.95M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.57M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.94M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.46M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.93M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.86M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.59M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.86M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.04M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.61M | – |